Drug intelligence / Profile preview

Eye-D

Development stage: Unknown
Lead developer: ViSci
Modality: Small Molecules
Administration: Implant, Ophthalmic

Overview

Eye-D is a controlled-release sub-conjunctival drug delivery implant developed by ViSci (a Bio-Light portfolio company) for the treatment of glaucoma. The device is designed to provide sustained delivery of latanoprost, a prostaglandin F2α analog, to reduce intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. By utilizing a sub-conjunctival implant, Eye-D aims to improve patient compliance and provide consistent therapeutic levels of medication compared to traditional daily eye drops. Clinical trials, including a Phase 2/3 equivalent study, have been completed for this asset.

Brand names: Eye-D
Other names: Latanoprost sub-conjunctival implantLatanoprost implant

Targets

PTGFR (Prostaglandin F2 alpha receptor)

Beyond the preview

Go deeper on Eye-D.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eye-D.

Explore the full profile